Avid Bioservices Inc (CDMO)

[biopharm]

4. Rahul Jasuja - Noble Life Science Partners noblelsp.com/research
RJ: ”Thanks for taking my question and glad to know that PS is now being recognized by big pharma and the immunology mafia so to say. So couple of questions pertaining to how PS with checkpoint inhibitors is differentiated from the conventional checkpoints inhibitors, like the CTLA-4, PD-1, PD-L1 pathways. From the data that's been represented at ImVacS, and also in discussions they’ve had with you guys, besides blocking just PS binding to its receptors on immune cells, there is an FC- FC gamma -based effector function leading to ADCC and so on and so forth - an immune effector function that other checkpoint inhibitors do not have blocking PD-1 or blocking CTLA-4. So, you’ve got a component here that is beyond other checkpoint inhibitors, that brings in an effector function that others do not have. Looking at that aspect or looking at some of the translational data, do you think that beyond the PD-1, PD-L1 non-immunogenic tumors, there is a possibility that PS blockade will have far more effect potentially driving [ph??] antigen presentation. Any comments on that?” ..
...
...

Where did the link go for shareholders to listen to this conference call again? Did Avid remove all those links ?



Rahul Rajendar Jasuja Ph.D.
CEO & Director, Pelican Therapeutics, Inc.
Age Total Calculated Compensation This person is connected to 1 Board Member in 1 organization across 7 different industries.

See Board Relationships
-- --
Background
Dr. Rahul Rajendar Jasuja, Ph.D. serves as the Chief Executive Officer and Director of Pelican Therapeutics, Inc. Dr. Jasuja served as a Senior Vice President and Senior Biotechnology Analyst at FBR Capital Markets & Co., Research Division from January 17, 2017 to April 2017. Dr. Jasuja has joined the equity research department's healthcare group and focused on the biotechnology sector. He has covered small and mid cap biotech companies. He served as the Managing Director of Biotechnology Research at NOBLE Capital Markets, Inc., Research Division. Dr. Jasuja served as Managing Director of Biotechnology Research at Noble Life Science Partners (NLSP). At NLSP, Dr. Jasuja was instrumental in building a fundamentally driven life sciences research effort. Prior to NLSP, Dr. Jasuja served as the Vice President of Corporate Development at Idera Pharmaceuticals, Inc. since January 1, 2010, focused on developing tolllike receptor based immunemodulators. At Idera, his role included business development, alliance management, pipeline strategy, technology communication for outlicensing efforts. He contributed to the development strategy of Idera's novel immune modulator (a tolllike receptor 7/9 antagonist) for autoimmune & inflammatory disease. Before that, he served as a Vice President of Equity Research of the Life Sciences and Vice President at MDB Capital Group LLC. Dr. Jasuja joined the MDB Capital Group LLC in 2004 and served as its Managing Director, Life Sciences Investment Banking. He has both a medical background as well as extensive institutional equity research experience. Earlier, he served as the Managing Director of Equity Research at MDB Capital, Investment Arm and MDB Capital Group LLC, Research Division. Previously, Dr. Jasuja served as a Senior Biotechnology Research Analyst at SOMA Partners, LLC, Research Division and Sagient Research Systems, Inc. He served as a Senior Biotechnology Research Analyst at Rodman & Renshaw Research; and Techvest, LLC, Research Division. He has more than twenty years of extensive and relevant experience and has background both within the biotechnology field and in the capital markets which has encompassed corporate business development, sell-side equity research and academia. Dr. Jasuja has been involved with Pelican's progress since 2013. Dr. Jasuja has conducted equity research, due-diligence and consulting for institutional investors in a wide range of areas in molecular medicine, including immunotherapy, autoimmunity and inflammation, metabolic diseases, oncology, cardiology, ophthalmology, regenerative medicine and tissue engineering. At Tufts Medical School, he taught and supervised medical and dental students in the field of immunology. He has conducted research in the areas of cell signaling, cancer biology, T-lymphocyte adhesion and activation and macrophage arachidonic acid metabolism. Throughout the years Dr. Jasuja has participated in numerous investor and business panels, authored and co-authored several biotechnology business white papers and has successfully built institutional life-sciences franchises through a long-term, deep technical research and analysis approach with educated life sciences investors and venture capitalist investors. He conducted doctoral and postdoctoral research at Harvard Medical School, Boston, in the Dept. of Hematology & Oncology at Beth Israel Deaconess Medical Center. He holds a B.S. in Microbiology & Biochemistry from St. Xavier's College, University of Bombay; an M.S. in Microbiology and Molecular Biology from the University of Montana, where he studied the role of bacterial cell wall immune modulators on arachidonic acid metabolism and inflammatory pathways in macrophages; and a Ph.D. in Immunology Tufts University School of Medicine, Boston, where he explored aspects of T cell activation and the subsequent regulation of adhesion receptors in the immune response.
Collapse Detail
Corporate Headquarters
3112 Windsor Road
Austin, Texas 78703

United States

Phone: [phone]
Fax: --
Board Members Memberships
CEO & Director
Pelican Therapeutics, Inc.
Education
MS
University Of Montana
PhD
Tufts University School of Medicine
BS
St. Xaviers College, Mumbai
Other Affiliations
Idera Pharmaceuticals, Inc.
Sagient Research Systems, Inc.
MDB Capital Group LLC
MDB Capital, Investment Arm
University Of Montana
Tufts University School of Medicine
FBR Capital Markets & Co., Research Division
MDB Capital Group LLC, Research Division
Rodman & Renshaw Research
FBR & Co.
St. Xaviers College, Mumbai
SOMA Partners, LLC, Research Division
NOBLE Capital Markets, Inc., Research Division
Techvest, LLC, Research Division